Archived 29: Amendment to January 25, 2022: NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age

Notice to reader

This is an archived version. Please refer to current COVID-19 vaccine pages:

Following consultation with HIV experts, NACI has updated the suggested list of conditions for children 5 to 11 years of age to be considered moderately to severely immunocompromised, for the purposes of a 3-dose primary series:

Please see NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age issued on January 25, 2022, for additional guidance.

Page details

Date modified: